Suppr超能文献

间变性淋巴瘤激酶(ALK)重排的非小细胞肺癌患者的临床病理和人口统计学特征:一项系统评价和荟萃分析

Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis.

作者信息

Fan Liang, Feng Yun, Wan Huanying, Shi Guochao, Niu Wenquan

机构信息

Department of Respiratory Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

State Key Laboratory of Medical Genomics, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

出版信息

PLoS One. 2014 Jun 24;9(6):e100866. doi: 10.1371/journal.pone.0100866. eCollection 2014.

Abstract

OBJECTIVE

This meta-analysis aimed to comprehensively examine the relationship between the clinicopathological and demographical characteristics and ALK rearrangements in patients with non-small cell lung cancer (NSCLC).

METHODS AND MAIN FINDINGS

In total, 62 qualified articles including 1178 ALK rearranged cases from 20541 NSCLC patients were analyzed, and the data were extracted independently by two investigators. NSCLC patients with ALK rearrangements tended to be younger than those without (mean difference: -7.16 years; 95% confidence interval (95% CI): -9.35 to -4.96; P<0.00001), even across subgroups by race. Compared with female NSCLC patients, the odds ratio (OR) of carrying ALK rearrangements was reduced by 28% (95% CI: 0.58-0.90; P = 0.004) in males, and this reduction was potentiated in Asians, yet in opposite direction in Caucasians. Likewise, smokers were less likely to have ALK rearrangements than never-smokers (OR = 0.33; 95% CI: 0.25-0.44; P<0.00001), even in race-stratified subgroups. Moreover, compared with NSCLC patients with tumor stage IV, ALK rearrangements were underrepresented in those with tumor stage I-III (OR = 0.58; 95% CI: 0.44-0.78; P = 0.0002). Patients with lung adenocarcinomas had a significantly higher rate of ALK rearrangements (7.2%) than patients with non-adenocarcinoma (2.0%) (OR = 2.25; 95% CI: 1.54-3.27; P<0.0001).

CONCLUSION

Our findings demonstrate that ALK rearrangements tended to be present in NSCLC patients with no smoking habit, younger age and tumor stage IV. Moreover, race, age, gender, smoking status, tumor stage and histology might be potential sources of heterogeneity.

摘要

目的

本荟萃分析旨在全面研究非小细胞肺癌(NSCLC)患者的临床病理和人口统计学特征与ALK重排之间的关系。

方法和主要发现

共分析了62篇合格文章,包括来自20541例NSCLC患者的1178例ALK重排病例,数据由两名研究人员独立提取。ALK重排的NSCLC患者往往比未发生重排的患者更年轻(平均差异:-7.16岁;95%置信区间(95%CI):-9.35至-4.96;P<0.00001),即使在按种族划分的亚组中也是如此。与女性NSCLC患者相比,男性携带ALK重排的比值比(OR)降低了28%(95%CI:0.58 - 0.90;P = 0.004),在亚洲人中这种降低更为明显,而在白种人中则相反。同样,吸烟者发生ALK重排的可能性低于从不吸烟者(OR = 0.33;95%CI:0.25 - 0.44;P<0.00001),即使在按种族分层的亚组中也是如此。此外,与肿瘤分期为IV期的NSCLC患者相比,ALK重排在肿瘤分期为I - III期的患者中比例较低(OR = 0.58;95%CI:0.44 - 0.78;P = 0.0002)。肺腺癌患者的ALK重排率(7.2%)显著高于非腺癌患者(2.0%)(OR = 2.25;95%CI:1.54 - 3.27;P<0.0001)。

结论

我们的研究结果表明,ALK重排倾向于出现在无吸烟习惯、年龄较轻且肿瘤分期为IV期的NSCLC患者中。此外,种族、年龄、性别、吸烟状况、肿瘤分期和组织学可能是异质性的潜在来源。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1964/4069179/41860fe3b4eb/pone.0100866.g001.jpg

相似文献

2
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.
Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD013453. doi: 10.1002/14651858.CD013453.pub2.
3
Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.
J Cancer Res Clin Oncol. 2014 Mar;140(3):453-60. doi: 10.1007/s00432-014-1584-8. Epub 2014 Jan 18.
4
Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations.
J Cancer Res Clin Oncol. 2016 Apr;142(4):833-43. doi: 10.1007/s00432-015-2081-4. Epub 2015 Dec 8.
5
TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.
J Cancer Res Clin Oncol. 2023 Sep;149(12):10041-10052. doi: 10.1007/s00432-023-04924-7. Epub 2023 Jun 1.
8
Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes.
J Cancer Res Clin Oncol. 2020 Apr;146(4):935-944. doi: 10.1007/s00432-019-03116-6. Epub 2020 Jan 1.
9
PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
J Cancer Res Clin Oncol. 2022 Dec;148(12):3557-3566. doi: 10.1007/s00432-022-04177-w. Epub 2022 Jul 20.

引用本文的文献

1
Aberrations in the glycosylation of receptor tyrosine kinases: A focus on lung adenocarcinoma.
Cytojournal. 2025 Jun 14;22:62. doi: 10.25259/Cytojournal_21_2025. eCollection 2025.
2
Age and smoking intensity in non-small cell lung cancer patients with the anaplastic lymphoma kinase fusion gene.
Contemp Oncol (Pozn). 2025;29(1):93-98. doi: 10.5114/wo.2025.148231. Epub 2025 Mar 7.
3
Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review.
Ther Adv Med Oncol. 2024 Dec 17;16:17588359241306940. doi: 10.1177/17588359241306940. eCollection 2024.
4
Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers.
BMC Cancer. 2024 Aug 3;24(1):951. doi: 10.1186/s12885-024-12737-1.
5
Anaplastic lymphoma kinase inhibitors-a review of anticancer properties, clinical efficacy, and resistance mechanisms.
Front Pharmacol. 2023 Oct 25;14:1285374. doi: 10.3389/fphar.2023.1285374. eCollection 2023.
6
A narrative review of methods for the identification of fusions in patients with non-small cell lung carcinoma.
Transl Lung Cancer Res. 2023 Jul 31;12(7):1549-1562. doi: 10.21037/tlcr-22-855. Epub 2023 Jul 11.
9
Anaplastic lymphoma kinase rearrangements in patients with non-small cell lung cancer in Jordan.
J Int Med Res. 2022 Jun;50(6):3000605221104181. doi: 10.1177/03000605221104181.
10
[Relationship between EGFR, ALK Gene Mutation and Imaging 
and Pathological Features in Invasive Lung Adenocarcinoma].
Zhongguo Fei Ai Za Zhi. 2022 Mar 20;25(3):147-155. doi: 10.3779/j.issn.1009-3419.2022.101.10.

本文引用的文献

1
A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives.
Indian J Cancer. 2013 Apr-Jun;50(2):80-6. doi: 10.4103/0019-509X.117007.
4
ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR.
PLoS One. 2013 Jul 26;8(7):e69016. doi: 10.1371/journal.pone.0069016. Print 2013.
5
Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
Exp Lung Res. 2013 Oct;39(8):328-35. doi: 10.3109/01902148.2013.819535. Epub 2013 Aug 6.
6
Immunohistochemical profiling of ALK fusion gene-positive adenocarcinomas of the lung.
Int J Surg Pathol. 2013 Oct;21(5):476-82. doi: 10.1177/1066896913489345. Epub 2013 Jun 20.
8
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
Clin Cancer Res. 2013 Aug 1;19(15):4273-81. doi: 10.1158/1078-0432.CCR-13-0318. Epub 2013 May 31.
9
Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.
Cancer J. 2013 May-Jun;19(3):238-46. doi: 10.1097/PPO.0b013e31829a68eb.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验